| NIB Holdings Limited (NHF) ORDINARY FULLY PAID |
Financials |
$3,422 |
2025 Full Year Results Investor Presentation
|
25 Aug 2025 8:11AM |
$7.710 |
$7.000 |
fallen by
9.21%
|
|
NHF - Price-sensitive ASX Announcement
Full Release
Key Points
- Revenue growth driven by pricing increases.
- Claims inflation reached 21.0% in second half of FY25.
- Implementation of claims recovery action plan.
- Service cost inflation decreased to 6% in line with sector CPI.
- Completion of core system upgrades improved service levels.
- Launch of new life insurance product range in Q4 FY25.
- New Zealand insurance revenue increased by 8.1%.
- Underlying operating profit affected by high claims inflation.
- Net promoter scores improved across various segments.
- Investment in AI and digital initiatives for growth.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| NIB Holdings Limited (NHF) ORDINARY FULLY PAID |
Financials |
$3,422 |
2025 Full Year Results ASX Announcement
|
25 Aug 2025 8:10AM |
$7.710 |
$7.000 |
fallen by
9.21%
|
|
NHF - Price-sensitive ASX Announcement
Full Release
Key Points
- FY25 group revenue increased to $3.6 billion, up 7.8% from FY24.
- Net profit after tax (NPAT) was $198.6 million, a 9.4% increase from FY24.
- Australian residents' health insurance achieved highest sales with 3.2% policyholder growth.
- NIB expanded services including dental networks and managed claims inflation effectively.
- International segment for students and workers saw a 23% increase in underlying operating profit.
- Fully franked dividend of 29.0 cents per share declared, matching FY24 payout.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| NIB Holdings Limited (NHF) ORDINARY FULLY PAID |
Financials |
$3,422 |
2025 Full Year Results ASX Announcement
|
25 Aug 2025 8:10AM |
$7.710 |
$7.000 |
fallen by
9.21%
|
|
NHF - Price-sensitive ASX Announcement
Full Release
Key Points
- Group revenue increased to $3.6 billion in FY25.
- Underlying operating profit was $239.2 million.
- Net profit after tax rose by 9.4% to $198.6 million.
- The highest ever sales were achieved in the Australian health insurance business.
- Policyholder growth was 3.2%, exceeding industry growth.
- The company faced claims inflation and economic challenges.
- NIB maintained a dividend of 29 cents per share.
- Strategic focus on core private health insurance and growth.
- Leveraging digital enhancements and AI for customer value.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| NIB Holdings Limited (NHF) ORDINARY FULLY PAID |
Financials |
$3,422 |
Appendix 4G and 2025 Corporate Governance Statement
|
25 Aug 2025 8:10AM |
$7.710 |
$7.000 |
fallen by
9.21%
|
|
| NIB Holdings Limited (NHF) ORDINARY FULLY PAID |
Financials |
$3,422 |
Dividend/Distribution - NHF
|
25 Aug 2025 8:10AM |
$7.710 |
$7.000 |
fallen by
9.21%
|
|
| Underwood Capital Limited (UWC) ORDINARY FULLY PAID |
Health Care |
$11 |
UWC FY25 Results Presentation
|
25 Aug 2025 8:10AM |
$0.050 |
$0.054 |
risen by
8%
|
|
| NIB Holdings Limited (NHF) ORDINARY FULLY PAID |
Financials |
$3,422 |
Appendix 4E and 2025 Annual Report
|
25 Aug 2025 8:10AM |
$7.710 |
$7.000 |
fallen by
9.21%
|
|
NHF - Price-sensitive ASX Announcement
Full Release
Key Points
- nib reported an underlying operating profit of $239.2 million and a net profit after tax of $198.6 million for FY25.
- Group revenue reached $3.6 billion, with a final dividend of 16 cents per share declared, totaling 29 cents for the year.
- Significant claims inflation occurred in Australian and New Zealand private health insurance businesses.
- nib achieved strong sales in its private health insurance business in Australia during FY25.
- The organization managed claims inflation to 4.9%, slightly affected by increased NSW Government charges.
- nib's Health Services division, including Honeysuckle Health, moved closer to profitability with a loss reduction to $7.0 million.
- The company completed the acquisition of the full ownership of Honeysuckle Health and Midnight Health.
- nib is focusing on integrating customer healthcare experiences through its Health Services division.
- Continued engagement in health management programs, with over 22,300 people enrolled to manage chronic conditions.
- The New Zealand business faced challenges due to high claims inflation and a soft economy.
- nib's capital management ensured a strong equity position and adherence to APRA standards.
- The Group's strategy involves expanding its digital and AI capabilities to enhance customer value.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| NIB Holdings Limited (NHF) ORDINARY FULLY PAID |
Financials |
$3,422 |
Appendix 4E and 2025 Annual Report
|
25 Aug 2025 8:10AM |
$7.710 |
$7.000 |
fallen by
9.21%
|
|
NHF - Price-sensitive ASX Announcement
Full Release
Key Points
- Profit for the year ended 30 June 2025 is $198.6 million.
- Basic earnings per share increased to 41.1 cents.
- Acquisition of full ownership in Honeysuckle Health Pty Ltd.
- Increased investment in The ItsMy Group Pty Ltd.
- Declared interim and final dividends totaling 29 cents per share.
- Directors' declaration confirms compliance with accounting standards.
- Strategic focus on health insurance sector investments.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Waratah Minerals Limited (WTM) ORDINARY FULLY PAID |
Materials |
$190 |
Becoming a substantial holder
|
25 Aug 2025 8:10AM |
$0.660 |
$0.490 |
fallen by
25.76%
|
|
| Underwood Capital Limited (UWC) ORDINARY FULLY PAID |
Health Care |
$11 |
FY25 UWC Appendix 4E and Annual Report
|
25 Aug 2025 8:10AM |
$0.050 |
$0.054 |
risen by
8%
|
|
UWC - Price-sensitive ASX Announcement
Full Release
Key Points
- UWC reported strong financial results for FY25, with significant revenue growth compared to the prior year.
- The company operates in the engineering and manufacturing sector, focusing on high-precision parts and assemblies for various industries including semiconductor, life sciences, and others.
- Profit after tax increased, reflecting operational efficiencies, margin improvements, and effective cost controls.
- UWC continued investments in capacity expansion, automation, and R&D to drive future growth.
- The Board recommended a final dividend, highlighting the company’s commitment to shareholder returns.
- UWC’s balance sheet remains robust, with healthy cash reserves and low gearing.
- Outlook for FY26 is optimistic, underpinned by a strong order book, ongoing customer demand, and strategic investments.
- ESG (Environmental, Social, and Governance) initiatives remain a priority, with progress made in sustainability and corporate governance practices.
- The company disclosed remuneration practices for directors and key management personnel, aligning with performance and market benchmarks.
- No material litigation or contingent liabilities were reported during the period.
- The annual report includes detailed disclosures in line with ASX and international financial reporting standards.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Traka Resources Limited (TKL) ORDINARY FULLY PAID |
Materials |
- |
General Meeting - Notice of Access
|
25 Aug 2025 8:10AM |
$0.003 |
$0.003 |
fallen by
0%
|
|
| Traka Resources Limited (TKL) ORDINARY FULLY PAID |
Materials |
- |
Notice of General Meeting/Proxy Form
|
25 Aug 2025 8:09AM |
$0.003 |
$0.003 |
fallen by
0%
|
|
| Vita Life Sciences Limited (VLS) ORDINARY FULLY PAID |
Health Care |
$133 |
Dividend/Distribution - VLS
|
25 Aug 2025 8:09AM |
$2.170 |
$2.450 |
risen by
12.90%
|
|
| Dyno Nobel Limited (DNL) ORDINARY FULLY PAID |
Materials |
$6,771 |
Update - Notification of buy-back - DNL
|
25 Aug 2025 8:09AM |
$3.120 |
$3.860 |
risen by
23.72%
|
|
| Nuix Limited (NXL) ORDINARY FULLY PAID |
Information Technology |
$381 |
FY25 Financial Results Presentation
|
25 Aug 2025 8:09AM |
$2.170 |
$1.125 |
fallen by
48.16%
|
|
NXL - Price-sensitive ASX Announcement
Full Release
Key Points
- Nuix Limited delivered year-on-year revenue growth driven by increased recurring revenue streams.
- Strong demand for digital investigation and analytics solutions contributed to the positive financial outcomes.
- The company invested in expanding its product portfolio, including new features and integrations.
- Operational efficiencies and cost management were prioritized to improve margin performance.
- Nuix strengthened its governance framework and risk management processes.
- Strategic partnerships and customer engagement initiatives supported market expansion.
- Resolved or addressed several ongoing legal and regulatory matters.
- FY25 guidance indicates continued revenue growth, careful cost management, and focus on profitability.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Nuix Limited (NXL) ORDINARY FULLY PAID |
Information Technology |
$381 |
Nuix Announces FY25 Results
|
25 Aug 2025 8:09AM |
$2.170 |
$1.125 |
fallen by
48.16%
|
|
NXL - Price-sensitive ASX Announcement
Full Release
Key Points
- Nuix announces FY25 guidance with strong anticipated growth in ACV and statutory revenue.
- ACV expected between $197m and $205m, reflecting 12.5%-17.2% growth.
- Statutory revenue forecasted at $205m-$215m, representing 11%-16.3% growth.
- Statutory EBITDA anticipated to be $48m-$55m.
- Growth to be driven by product innovation, sales and marketing investment, and customer engagement.
- Focus on expanding product portfolio and increasing recurring revenue.
- Strategic investments and disciplined capital allocation will support long-term growth.
- Continued focus on operational efficiencies while investing in future expansion.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Lindsay Australia Limited (LAU) ORDINARY FULLY PAID |
Industrials |
$214 |
FY2025 Results investor Presentation
|
25 Aug 2025 8:09AM |
$0.735 |
$0.585 |
fallen by
20.41%
|
|
LAU - Price-sensitive ASX Announcement
Full Release
Key Points
- Lindsay Australia Limited focuses on transport and rural services as core business activities.
- Strong revenue growth and careful cost management were reported for FY2025.
- Investments in fleet, technology, and infrastructure support operational efficiencies.
- Strategic acquisitions and partnerships have expanded service offerings and market reach.
- Continued commitment to safety and environmental sustainability is emphasized.
- Industry challenges include regulatory changes and weather impacts on operations.
- The outlook for FY2026 is positive, driven by organic growth and further strategic investment.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Nuix Limited (NXL) ORDINARY FULLY PAID |
Information Technology |
$381 |
Appendix 4E and Annual Financial Report FY25
|
25 Aug 2025 8:09AM |
$2.170 |
$1.125 |
fallen by
48.16%
|
|
NXL - Price-sensitive ASX Announcement
Full Release
Key Points
- Nuix Limited reported a 6% increase in statutory revenue to $180.2 million for FY24.
- Statutory net profit after tax (NPAT) was $6.6 million.
- EBITDA for the year was $36.5 million.
- The company generated $36.4 million in cash from operating activities.
- Strong customer retention and growth in new markets contributed to performance.
- Continued investment in research and development and product innovation.
- The board did not declare a dividend for the year.
- Internal control and risk management frameworks were enhanced.
- Ongoing litigation includes a class action and ASIC proceedings related to historical events.
- The report includes audited financial statements and detailed notes on accounting policies.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Vita Life Sciences Limited (VLS) ORDINARY FULLY PAID |
Health Care |
$133 |
Half Year Presentation
|
25 Aug 2025 8:09AM |
$2.170 |
$2.450 |
risen by
12.90%
|
|
VLS - Price-sensitive ASX Announcement
Full Release
Key Points
- Group revenue for H1 2023 was $29.4 million, a 9% year-on-year increase.
- Net profit after tax was $4.2 million, up 13% from the prior corresponding period.
- Malaysia, Australia, and Indonesia contributed strongly to growth.
- Expanded product offerings and distribution channels.
- Continued investment in marketing, research, and digital initiatives.
- Operational efficiencies and improved inventory management implemented.
- Maintained a cash position of $19.6 million with no debt.
- Declared interim dividend of 3.25 cents per share.
- Ongoing focus on product innovation, brand building, and geographic expansion.
- Board and management remain confident in outlook for continued growth.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| AIC Mines Limited (A1M) ORDINARY FULLY PAID |
Materials |
$562 |
Investor Presentation
|
25 Aug 2025 8:09AM |
$0.320 |
$0.705 |
risen by
120.31%
|
|
| Vita Life Sciences Limited (VLS) ORDINARY FULLY PAID |
Health Care |
$133 |
Half Year Accounts
|
25 Aug 2025 8:08AM |
$2.170 |
$2.450 |
risen by
12.90%
|
|
VLS - Price-sensitive ASX Announcement
Full Release
Key Points
- Interim financial report covers half year ended 30 June 2023.
- Directors' report summarizes company operations, financial performance, and future outlook.
- Revenue and net profit figures for the period are provided.
- Principal activities remain the development and distribution of health supplements and products.
- Company continues to focus on operational efficiency and strategic growth.
- Board reviewed risk management and corporate governance frameworks.
- No significant changes in the company's state of affairs or principal activities during the period.
- Dividends declared and paid during the period are disclosed.
- Financial statements prepared in accordance with AASB 134 and Australian Accounting Standards.
- Auditor's independence declaration included to ensure transparent reporting.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| PWR Holdings Limited (PWH) ORDINARY FULLY PAID |
Consumer Discretionary |
$792 |
Retirement of Chairman
|
25 Aug 2025 8:08AM |
$7.750 |
$7.870 |
risen by
1.55%
|
|
| Thunderbird Resources Limited (THB) ORDINARY FULLY PAID |
Materials |
- |
High-Grade Surface Gold at Bear Hill and New Kojak Target
|
25 Aug 2025 8:08AM |
$0.014 |
$0.019 |
risen by
40.74%
|
|
THB - Price-sensitive ASX Announcement
Full Release
Key Points
- Thunderbird Resources Limited (THB) announced high-grade gold discoveries at Bear Hill and New Kojak targets.
- The discoveries were made within the Burchell Lake Gold Project, Ontario, Canada.
- Surface sampling and mapping returned significant gold assay results.
- Assays confirmed the presence of high-grade gold mineralization at surface.
- The new results highlight the exploration and economic potential of the Bear Hill and New Kojak target areas.
- THB plans to prioritize further exploration and drilling at these targets.
- The findings are significant for the company’s ongoing exploration strategy.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Auric Mining Limited (AWJ) ORDINARY FULLY PAID |
Materials |
$42 |
Burbanks Mill Agreement Executed
|
25 Aug 2025 8:08AM |
$0.165 |
$0.225 |
risen by
36.36%
|
|
AWJ - Price-sensitive ASX Announcement
Full Release
Key Points
- Auric Mining Limited (AWJ) executed a binding Ore Purchase Agreement with Burbanks Processing Pty Ltd.
- The agreement involves processing ore from Jeffreys Find Gold Mine at the Burbanks Mill.
- A minimum of 150,000 tonnes of gold ore will be processed during 2024 and 2025.
- The commercial terms for processing have been pre-agreed.
- Jeffreys Find Gold Mine is a 50/50 joint venture between AWJ and BML Ventures Pty Ltd.
- The agreement ensures access to necessary processing capacity for AWJ's ongoing mining operations.
- The partnership supports project cash flow and operational stability.
- The deal is expected to benefit both Auric Mining and Burbanks Mill through reliable supply and market access.
- Management emphasized the significance of the agreement for operational planning and shareholder value.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Nanoveu Limited (NVU) ORDINARY FULLY PAID |
Information Technology |
$54 |
Nanoveu Establishes Key U.S. Sales Network
|
25 Aug 2025 8:08AM |
$0.086 |
$0.050 |
fallen by
41.86%
|
|
NVU - Price-sensitive ASX Announcement
Full Release
Key Points
- Nanoveu Limited establishes a key U.S. sales network by partnering with Medline Industries, LP.
- Medline is the largest privately held manufacturer and distributor of medical supplies in the U.S.
- Agreement covers distribution of Nanoveu’s antiviral screen protector products in the U.S. healthcare sector.
- Partnership expected to expand Nanoveu's market reach and access new customer bases.
- Agreement supports Nanoveu’s growth strategy and global footprint expansion.
- Collaboration leverages Medline’s extensive distribution channels in the healthcare industry.
- Increased demand for antiviral solutions in healthcare is a driver for this partnership.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
Call 1300 880 160
Start a chat
Schedule a call
